BPC
TVRD

Banque Pictet & Cie’s Tvardi Therapeutics TVRD Stock Holding History

Banque Pictet & Cie’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-280
Closed -$171K – 490
2014
Q2 		$171K Buy
+280
New +$151K ﹤0.01% 436

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Banque Pictet & Cie's TVRD Position: Q3 2014 in Review

Banque Pictet & Cie sold out of Tvardi Therapeutics (TVRD) in Q3 2014, closing a stake of 280 shares — an estimated $171K sold.

Banque Pictet & Cie first reported a position in TVRD in Q2 2014 and held it in 1 quarter. The position peaked at $171K in Q2 2014. 56 funds tracked by Wall St. Rank hold TVRD as of Q3 2014.

  • Banque Pictet & Cie reported no remaining Tvardi Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Banque Pictet & Cie sold 280 Tvardi Therapeutics shares in Q3 2014, an estimated $171K.
  • Banque Pictet & Cie first reported a position in Tvardi Therapeutics in Q2 2014 and held it in 1 quarter.
  • Banque Pictet & Cie's Tvardi Therapeutics position peaked at $171K in Q2 2014.
  • 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2014.

Based on Banque Pictet & Cie's 13F filing for Q3 2014, filed 7 Nov 2014.